(WOIO) - Tuesday the Cuyahoga County Health Department issued this statement:
Cuyahoga County Health Officials have not received recalled lots of Sanofi vaccine to date.
This morning, public health officials learned that Sanofi Pasteur issued a voluntary recall of swine flu vaccine for infants. After assessing local vaccine inventory records, it was determined that the vaccine in question was not part of the shipments received by local public health agencies.
"To the best of our knowledge, none of the three health departments in our County have received any of the vaccine in question" - says Terry Allan, Health Commissioner of the Cuyahoga County Board of Health.
According to Matt Carroll, Director of the Cleveland Department of Public Health, "The Centers for Disease Control states there is no need to re-administer a dose to those who received vaccine from these lots."
"It is recommended for all 2009 U1N1 vaccines, all children less than 10 years old should get the recommended two doses of Hi Ni vaccine approximately a month apart for the optimal immune response. So, children less than 10 years old who have only received one dose of vaccine thus far should still receive a second dose of 2009 H1NI vaccine" advises Dr. Scott Frank, Medical Director and Health Commissioner of Shaker I-Its Health Department.
Hundreds of thousands of doses of H1N1 flu vaccine are being recalled after tests indicated they may not be potent enough to protect against the virus. The Centers for Disease Control and Prevention notified doctors about the recall today.
The doses are pre-filled syringes intended for young children, ages six months to almost three years. There is no health hazard and the FDC and the CDC recommend not repeating the dose for children who received vaccine from these lots. The CDC says parents of children who received vaccine from the recalled lots do not need to take any action other than to complete the two-dose immunization series.
Additional information for the Centers for Disease Control and Prevention:
As part of its quality assurance program, the manufacturer, Sanofi Pasteur, performs routine, ongoing stability testing of its influenza A (H1N1) vaccine after the vaccine has been shipped to providers. Stability testing means measuring the strength (also called potency) of a vaccine over time. It is performed because sometimes the strength of a vaccine can go down over time. On December 7, Sanofi Pasteur notified CDC and FDA that the potency in one batch (called a "lot") of pediatric syringes that had been distributed was later found to have dropped below a pre-specified limit. As a result of this finding, Sanofi Pasteur tested additional lots and found that three other lots that had been distributed also had an antigen content that, while properly filled at the time of manufacturing, was later measured to be below pre-specified limits. This means that doses from these four vaccine lots no longer meet the manufacturer's specifications for potency. Sanofi Pasteur will send providers directions for returning any unused vaccine from these lots.
Potency (or strength) is determined by the measurement of the concentration of the active ingredient (also called antigen) in the H1N1 vaccine.
No. There are no safety concerns with these lots of H1N1 vaccine. All lots successfully passed pre-release testing for purity, potency and safety.
No. The vaccine potency is only slightly below the "specified" range. The vaccine in these lots is still expected to be effective in stimulating a protective response despite this slight reduction in the concentration of antigen. There is no need to re-administer a dose to those who received vaccine from these lots. However, as is recommended for all 2009 H1N1 vaccines, all children less than 10 years old should get the recommended two doses of H1N1 vaccine approximately a month apart for the optimal immune response. Therefore, children less than 10 years old who have only received one dose of vaccine thus far should still receive a second dose of 2009 H1N1 vaccine.
Parents of children who received vaccine from the recalled lots do not need to take any action, other than to complete the two-dose immunization series if not already completed.
Vaccine doses with the following lot numbers are included in the recall:
0.25 ml pre-filled syringes, 10-packs (NDC # 49281-650-25, sometimes coded as 49281-0650-25):
0.25 ml pre-filled syringes, 25-packs (NDC # 49281-650-70, sometimes coded as 49281-0650-70):
Approximately 800,000 doses of vaccine in these lots were distributed to providers.
The potency problem described here is specific to the four lots of Sanofi Pasteur's pediatric H1N1 vaccine in 0.25 mL pre-filled syringes. Sanofi Pasteur is investigating what caused the problem. The same vaccine packaged in other dosing forms, such as pre-filled syringes for older children adults, and multi-dose vials, continues to meet specifications. This recall does not affect H1N1 vaccine produced by other manufacturers.
No. The lots being recalled passed all quality controls and met all specifications before they were shipped.
All vaccines are routinely tested for purity, potency and safety prior to release. The four lots of vaccine met all required specifications at the time of release and shipment to distribution centers. The vaccine provided in multi-dose vials and the single-dose, 0.5 mL pre-filled syringes for persons 36 months and older continues to meet all specifications.
Sanofi Pasteur will send a notification to providers who received doses from any of the four lots of vaccine so that they can return any unused vaccine.
Vaccine from these four lots was distributed throughout the United States.